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REVIEW
Infection prevention and control in cystic fibrosis: a systematic review of
interventions
Nicola J Rowbotham , Sally C Palser, Sherie J Smith and Alan R Smyth
Evidence Based Child Health Group, Division of Child Health, Obstetrics & Gynaecology, Queens Medical Centre, Nottingham, UK
ABSTRACT
Introduction: Cystic fibrosis is a life-limiting genetic condition characterized by recurrent pulmonary
infection. Acquisition of infection can occur from environmental reservoirs, person-to-person transmis-
sion and from the healthcare environment. Primary prevention of infections through infection preven-
tion and control measures is an important strategy in cystic fibrosis care.
Areas covered: Here we present a systematic review of the evidence base around infection prevention
and control in cystic fibrosis. We found 36 studies and 7 guidelines that met our inclusion criteria.
Strategies covered include cohort segregation, individual segregation, hand hygiene, facemasks, com-
bination strategies, equipment strategies, and adherence. Quality of evidence overall was deemed low
or very low. Most guideline recommendations have little or no evidence to support them.
Expert opinion: Although low quality, there is an abundance of evidence suggesting segregation is
beneficial in reducing pathogen spread. Undertaking high-quality studies may, therefore, be ethically
challenging. Large-scale registry studies may provide a better strategy for answering questions on the
efficacy of infection control policy. With the rise of antibiotic resistance, effective eradication of cystic
fibrosis pathogens is becoming more difficult so primary prevention through infection control will
become increasingly important over the coming years.
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1. Introduction
Cystic fibrosis (CF) is the commonest autosomal recessive
life-limiting condition in Caucasian populations, affecting
between 70,000 [1] and 100,000 [2] people worldwide.
Median age of death and median predicted survival have
both increased significantly over recent decades [3]. The
CF gene is located on chromosome 7 and mutations lead
to absence or dysfunction of the cystic fibrosis transmem-
brane conductance regulator (CFTR), a protein which forms
a chloride channel in cell membranes in many body sys-
tems. In respiratory epithelial cells, lack of CFTR function
leads to failure of the mucociliary escalator, stasis of
respiratory secretions and opportunistic infection. CF is
characterized by a cycle of recurrent pulmonary infection,
inflammation and tissue damage which may ultimately
lead to respiratory failure and death [4].
The prevalence of respiratory organisms affecting indivi-
duals with CF changes from infancy, through childhood and
into adult life [2]. In preschool children, the commonest
respiratory infections are Staphylococcus aureus and
Haemophilus influenzae. In older children, intermittent infec-
tion with Pseudomonas aeruginosa (PA) becomes more pre-
valent and over half of the individuals with CF will have
a chronic pulmonary infection with this organism by their
early twenties [1,2]. Some strains of PA are antibiotic resis-
tant and transmissible between patients [5]. Infection with
PA is associated with a greater risk of death and a more
rapid decline in lung function in people with CF [6].
Eradication of early infection with PA can delay the onset
of chronic infection. Once the chronic infection has devel-
oped, eradication is impossible [7]. The prevalence of some
organisms varies greatly between countries. Methicillin-
resistant S. aureus (MRSA) is present in around 3% of adults
with CF in the UK [2] but in the US [1] the prevalence
reaches over 30%. Other organisms are less prevalent but
are highly antibiotic resistant with evidence of transmission.
This category includes Burkholderia cepacia complex (BCC)
and non-tuberculous mycobacteria (NTM), particularly
Mycobacterium abscessus complex. Finally, a number of
gram-negative organisms are found in sputum samples
from CF individuals whose status as a CF pathogen has
not yet been fully established, including Stenotrophomonas
maltophilia and Achromobacter xylosoxidans.
Infection in the CF airways drives inflammation and leads
to bronchiectasis. Effective treatment is limited by antibiotic
resistance and the favorable niche provided by the CF lung.
Primary prevention of these infections, through infection
prevention and control, is, therefore, an important strategy.
Prevention requires an understanding of how pulmonary
infection is acquired in CF, and the evidence behind differ-
ent modes of acquisition will be briefly considered here
under the following headings:
CONTACT Alan R Smyth alan.smyth@nottingham.ac.uk Evidence Based Child Health Group, Division of Child Health, Obstetrics & Gynaecology, Queens
Medical Centre, E Floor East Block, Nottingham NG7 2UH, UK
Supplementary data for this article can be accessed here
EXPERT REVIEW OF RESPIRATORY MEDICINE
2019, VOL. 13, NO. 5, 425–434
https://doi.org/10.1080/17476348.2019.1595594
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
● Out of hospital acquisition through environmental reservoirs
● Person to person transmission
● Acquisition from the healthcare environment
1.1. Out of hospital acquisition through environmental
reservoirs
Many CF pathogens, including PA, NTM, and BCC are found in
soil and water. They may also contaminate similar environments
in the home. PA has been found in the home environment,
commonly in sinks and drains [8,9]. However, in only 9 out of
50 patients with acute PA infection was an identical strain iso-
lated in both the patient and their home environment [9].
Outside the home, swimming pools [10] and paddling pools
[11] may be contaminated with PA, though regular use of
a swimming pool has been found to reduce the risk of PA
acquisition in CF and use of hot tubs had no effect [12]. Living
in a location with warmer temperatures, greater humidity, and
increased rainfall also increases the risk of acquisition of PA,
whilst living further from the equator reduces the risk [13].
Geography also plays a part in NTM infection. In the US, the
prevalence of NTM in CF patients is greatest in states in the
West or the South East of the country and prevalence increases
with increasing humidity [14]. In the US [1], NTM infection in
people with CF is mainly Mycobacterium avium complex
whereas, in the UK [2], M. abscessus complex predominates. For
BCC there is no phenotypic correlation between clinical and soil
isolates [15], though a study of clinical and agricultural
B. cenocepacia samples found strains from onion rhizospheres
that were identical on multilocus sequence typing (MLST) to the
PHDC clinical strain [16].
1.2. Person to person transmission
Transmission of an antibiotic-resistant strain of PA was first
documented in the CF center in Copenhagen in 1986 [17]. Ten
years later, genomic finger-printing techniques showed that
a beta-lactam resistant clone of PA was responsible for an out-
break in a CF center in Liverpool [5]. This was subsequently
named the Liverpool Epidemic Strain and carries a worse prog-
nosis than infection with ‘unique’ strains of PA [18]. The pivotal
study of newborn screening for CF found that an increase in PA
infection, amongst infants diagnosed through screening, was
attributable to one of two study centers allowing mixing of
young children with older patients. The median time from diag-
nosis by newborn screening to PA acquisition was 289 weeks in
the center which employed segregation versus 52 weeks in the
center which did not [19]. More recently, whole genome sequen-
cing has shown transmission of multidrug-resistant NTM
between patients with CF at a center in Cambridge, despite
infection control measures [20]. The route of transmission was
uncertain, but epidemiological analysis suggests this may be
indirect. There is also evidence for person to person transmission
of BCC. Govan et al. [21] used pulsed-field gel electrophoresis to
identify a B. cenocepacia clone, subsequently named ET12, as the
source of an outbreak involving two UK CF Centres. Significant
social contact both within and outside of the CF Centre was
blamed for transmission [21].
Environmental contamination by the Liverpool Epidemic Strain
of PA was detected on respiratory equipment in the immediate
vicinity of infected CF patients and in air samples taken from the
patient’s room and the corridor outside [22]. Although this epi-
demic strain of PA could survive longer thanother PA strains ondry
surfaces, no environmental reservoir was found. The researchers
concluded that airborne dissemination is an importantmechanism
of the patient to patient spread for this organism. The Liverpool
Epidemic Strain of PA (which is highly antibiotic resistant) has the
ability to cause superinfection in CF patients who already have
chronic infection with another strain of PA (which may be less
resistant) [22]. These observations demonstrate that cohort segre-
gation of CF patients by organism may still allow patients to
acquire a strain of the same organism which is more difficult to
treat and carries a worse prognosis. More recent studies have
investigated the potential for CF patients to generate infected
aerosols and droplet nuclei, as well as looking at how far these
infectious particles travel and how long they can persist. A droplet
nucleus (originally described in tuberculosis) is the residue of
a cough aerosol droplet which is left after evaporation and which
contains any organisms present in the original aerosol. Droplet
nuclei remain airborne in air currents found in any occupied room
and are rapidly dispersed [23]. Wood and colleagues [24], used an
Andersen impactor to study cough aerosols in CF. The majority of
CF patients studiedwere found to produce aerosols containing PA
during coughing, in contrast to talkingwhich produced little viable
organism. Aerosols produced by CF patients during coughing
contained PA in droplet nuclei of respirable size (<4.7 μm). These
investigators also studied the effect of patients wearing a mask,
and we discuss this below in the results of our systematic review.
The airborne transmission of other organisms has been investi-
gated using the same approach. S. aureus (both sensitive strains
and MRSA) and gram-negative bacteria (including Burkholderia
species, S. maltophilia and Achromobacter species) are aerosolized
during coughing, can travel up to 4 m and remain viable within
droplet nuclei for up to 45 min [25] as can M. abscessus com-
plex [26].
1.3. Acquisition from the healthcare environment
In an environmental study from a pediatric ward in Germany [27],
themajority of sink drainswere found to be contaminatedwith PA,
whereas contaminationwith BCCwas uncommon. Transmission of
the PAwas demonstrated from CF patients or the environment, to
Article highlights
● Recurrent pulmonary infection in cystic fibrosis can lead to tissue
damage and ultimately respiratory failure and death.
● Acquisition can occur through person-to-person transmission, from
the healthcare environment and environmental reservoirs.
● There is an abundance of low-quality evidence to support cohort and
individual segregation measures as methods to prevent transmission
between patients.
● Face masks are effective at reducing the release of potential infective
Pseudomonas aerosols and are tolerable to participants in studies of
adults with cystic fibrosis.
● With the rise of antibiotic resistance, primary prevention through
infection control will become increasingly important.
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other patients or to hospital staff. One episode of transmission of
PA from the hospital environment to a CF patient was documen-
ted. The same study found that PA or BCC embedded in sputum
can contaminate the hands of patients or health professionals and
can be transmitted by shaking hands for up to 180min. Bryant and
colleagues [26] propose environmental fomite contamination as
another mechanism of indirect transmission of M. abscessus com-
plex. They identified identical clones in three patients with novel
infection following an inpatient stay in a roompreviously occupied
by a patient with knownM. abscessus complex infection. Identical
isolates were obtained from environmental sampling of the room.
S. maltophilia was found in the respiratory secretions of
a quarter of patients in a pediatric CF center in Leeds [28].
Genotyping of environmental and patient samples led to the
conclusion that person to person transmission was unlikely but
that there may have been multiple, independent acquisitions of
the organism from a variety of environmental sites both within
and outside the hospital.
Potential CF pathogens have been found on nebulizers
[29–33] but only in a few instances have these been consistent
with pathogens identified from the patient’s respiratory sam-
ples [34,35]. Increased use of aerosolized medications was
found to be a risk factor for PA acquisition in a mathematical
model of PA risk factors [36]. Epidemic PA was not found on
spirometers [37] in the investigation of an outbreak, though
contaminated nebulizers can transmit PA and BCC to clean
hands [27]. Respiratory filters are effective at preventing the
passage of pathogens into the machine [38].
1.4. Infection control strategies
A number of infection prevention and control guidelines have
been produced for CF (see Table 1). Guideline recommenda-
tions include:
● Cohort segregation of CF patients (based on carrier sta-
tus of organisms).
● Individual segregation of CF patients.
● Personal hygiene methods such as handwashing.
● Wearing personal protective equipment such as gloves,
gowns, andmasks by both patients and health-care workers.
● Cleaning and disinfection of areas and equipment.
Here we systematically review the evidence base for infection
prevention and control strategies in CF. We intend to highlight
what is known about strategies to prevent infection and identify
where further research is needed. This will help the CF commu-
nity understand what constitutes appropriate prevention strate-
gies and reduce the burden of unnecessary measures.
2. Methods of systematic review
Our full protocol can be found on PROSPERO (CRD42018109999)
[39]. Studies (of any type) and guidelines which included inter-
ventions or strategies for infection prevention and control in
people of any age with a formal diagnosis of CF and in English
were eligible for inclusion. We excluded epidemiological studies,
non-patient studies, non-systematic review articles and studies
relating to vaccination or eradication.
We undertook a search for studies of the following data-
bases in October 2018: EMBASE, MEDLINE, CINAHL, Cochrane
Library and PubMed [40–44]. Search strategies were devised
iteratively and search terms kept broad to increase sensitivity
(Supplementary file1).
Clinical guidelines published in the last 10 years were
identified by searching the following guideline repositories:
CF Trust; CF Foundation; European Cystic Fibrosis Society
(ECFS); National Institute for Health and Care Excellence
(NICE); National Guidelines Clearing House; Cystic Fibrosis
Federation Australia. Search results were downloaded to
Endnote (vX7) [45] and checked for duplicates. The online
program Covidence [46] was used for screening by two
reviewers with arbitration by a third in case of disagreement.
The resulting studies were recorded in Microsoft Excel [47]
and organized into categories. Strength of evidence for each
category was assessed using GRADE [48].
3. Results of systematic review
Our searches identified 3485 references after duplicates had been
removed, 41 (36 studies) of these met the criteria for inclusion. We
excluded 3070 on title and abstract alone and 374 from the full-
text article with reasons described (Figure 1. Preferred Reporting
Items for Systematic Reviews and Meta-Analyses chart).
Within the included studies there were two randomized con-
trolled trials, with themajority (n = 22) consisting of ‘before-after’
studies. There were five interventional studies, two prospective
cohort studies, two comparative studies and one audit looking
into adherence to infection control policies. Two systematic
Table 1. Evidence within guideline recommendations.
Guideline source Guideline Year
Total number of
recommendations included
Level of evidence
High Low None Expert opinion
NICE [37] Cystic fibrosis: diagnosis and
management
2017 6 5 1
CF Trust [38] Antibiotic treatment for cystic
fibrosis. Third edition.
2009 9 4 5 2
CF Trust [39] NTM guidelines 2018 34 34
CF Foundation [40] Infection prevention and control
clinical care guidelines
2014 87 40 6 2 39
CF Foundation [41] Eradication of initial P. aeruginosa
clinical care guidelines
2013 3 1 1 1
CF Foundation [42] Nontuberculous Mycobacteria
clinical care guidelines
2015 8 8
CF Federation of Australia [43] Infection control guidelines 2012 21 21
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reviews for interventions of infection prevention and control in
CF met our inclusion criteria so their included studies were
double-checked for inclusion. Characteristics of the included
studies are presented in Supplementary file 2.
We found seven guidelines [49–53] with reference to infec-
tion prevention and control policies. These are summarised in
Table 1 which shows the guideline source, number of recom-
mendations, and level of evidence for these. Most guideline
recommendations had little or no evidence to support them.
4. Evidence for infection control and prevention
strategies
Table 2 shows the strength of evidence for each category
discussed below.
4.1. Cohort segregation
4.1.1. Inpatient cohort segregation
Three studies have reported on the effectiveness of cohort seg-
regation in inpatients. Physical separation of inpatients colonized
with BCC (then known as Pseudomonas cepacia) led to a sharp
decline in incidence from 8.2% in 1983 to 1.7% in1984 in one
North American CF center [54]. Paul et al. [55] showed that, when
comparing Australian hospitals, a CF center that practiced cohort
segregation of inpatients with BCC had no evidence of cross-
infection between patients. In contrast, in a center where there
was no cohort segregation, the same endemic strain was found
in 19 of 20 patients [55]. Chen et al. [56] also showed that
cohorting of inpatients based on BCC infection status led to
a drop in incidence.
4.1.2. Outpatient cohort segregation
One RCT has looked into the effectiveness of cohort segrega-
tion of outpatients by PA status [57]. This showed no clinically
significant difference in 10-year incidence of PA between CF
children diagnosed by newborn screening and randomized to
either segregated or mixed clinics. However, the authors
noted that at the time of the study one clinic moved into
a much newer building with more space and better provision
of hygienic precautions. They speculated that reduced
patient–patient interactions in the new building confounded
the study, with the median time to initial PA acquisition
increasing from 1.7 years in the old building to 5.0 years in
the new. Furthermore, the study lacked statistical power.
There are two before–after studies which looked at out-
patient segregation [58,59]. Lee et al. [58] showed a drop in
the prevalence of chronic PA, in children under 11 years, from
23.8% to 4.3% over a 10-year period, following the introduc-
tion of cohort segregation. Similarly, McKay et al. [59] noted
a drop in acquisition of mucoid PA following the introduction
of ‘color-coded’ (by age and PA status) clinic segregation.
Figure 1. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) chart.
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Table 2. Quality of evidence for infection prevention and control strategies.
Strategy/
recommendation
Number of
studies Study design Direction of findings GRADE GRADE description
Cohort segregation
Inpatient 3 [54–56] 2 before and after
studies, 1
comparative
epidemiological
study
All three studies supported inpatient
cohorting
Low The quality of evidence is low based on
the study design. However, all three
studies support inpatient cohorting.
Outpatient 3 [57–59] 1 RCT, 2 before and
after studies
The RCT and one of the before and
after studies found no change in
acquisition of PA after segregation
in outpatient clinics. The third study
supported segregation for mucoid
PA but not non mucoid PA.
Very low Although there is an RCT which
contributes to the evidence for this
strategy, there is heterogeneity
amongst the results of the three
studies. The before and after studies
do not have a control group and so
it is difficult to control for
confounding variables.
Combined in and
outpatient
7 [60–68] 7 Before and after
studies
All seven studies found evidence to
support cohort segregation in the
inpatient/outpatient setting. Two of
the studies showed only a decrease
in epidemic strains.
Low The quality of evidence is low based
on the study design but there are
seven studies which all support
inpatient/outpatient cohorting.
Other 3 [69–71] 1 before and after
study, 1 prospective
cohort study and
one comparative
epidemiological
study
All three studies supported cohort
segregation
Very low The three studies contributing evidence
to this strategy are heterogeneous in
their design and setting.
Individual segregation
Combined in and
outpatient
1 [72] 1 before and after
study
Supported individual segregation
measures
Very low The study contributing evidence was
a before and after study but there
was no control group to compare
the effect of segregation. The
evidence was downgraded due to
there only being one study.
Hand hygiene
Outpatient 1 [73] 1 before and after
study
Supported hand hygiene measures Very low The study contributing evidence was
a before and after study but there
was no control group to compare
the effect of segregation. The
evidence was downgraded due to
there only being one study. The
study authors highlight the fact that
it was difficult to control for
confounding factors, particularly
transmission of PA outside the clinic.
Face masks
Outpatient/lab based 3 [24,74–76] 3 The two interventional studies found
face masks to be effective in
reducing aerosol PA load. The RCT
found no difference in exam room
contamination rate.
Low Although there is an RCT which
contributes to the evidence for
this strategy, the outcome is exam
room contamination rate which is
an indirect measure of evidence
for the effectiveness of face masks
in reducing spread of infection.
The remaining two studies are not
RCTs and therefore the quality of
the evidence is deemed to be low.
Combination of
strategies
7 [56,77–82] 6 before and after
studies, 1
prospective cohort
study
6/7 studies found combinations of
infection control strategies to be
effective in reducing infection rates.
The remaining study showed no
difference after the strategies were
introduced.
Very low The quality of the evidence has been
downgraded to very low due to
the heterogeneity in the strategies
implemented and study designs.
Social events 1 [83] 1 The findings support the suggestion
that transmission of P cepacia is
through social contact.
Very low With only one small study
contributing to the evidence for
reducing social contact to prevent
spread of infection, the quality of
evidence has been downgraded to
very low.
Equipment strategies 3 [29,84,85] 3 intervention studies The three studies looked at different
interventions and outcomes. Not
possible to combine results.
Very low The evidence was downgraded to
very low due to heterogeneity in
study interventions and outcomes.
Adherence 2 [86,87] 1 audit, 1 before and
after study
Both studies reported on compliance
after the implementation of IP&C
guidelines. The audit did not give
a before comparison.
Very low Downgraded due to there being only
two studies with different designs
but both looking at compliance.
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4.1.3. Combined inpatient and outpatient cohort
segregation
Many before–after studies have shown combined inpatient and
outpatient cohort segregation to be effective in preventing the
spread of infection. Segregation of patients without PA, with PA,
andwith amulti-resistant strain of PA, by wards (as inpatients) and
by different days (outpatients) was shown to decrease incidence of
both new PA acquisition in those previously uncolonized, and
superinfectionwith a transmissible strain in patients with previous,
unique, PA [60]. Cohort segregation was also shown to reduce PA
incidence by Frederiksen et al. [61]. Cohort segregation of clinics
and strict inpatient isolation measures controlled the spread of
transmissible PA in adults in Manchester, UK [62] and the
Australian epidemic strain of PA in children in Victoria, Australia
[63,64]. Ashish et al. [65,66] showed that their cohort segregation
policy in both outpatient clinics and for inpatients by cohorting on
separate wards was effective in preventing the spread of the
Liverpool epidemic strain of PA in their clinic population.
Whiteford et al. [67] showed that following an outbreak of BCC,
simple cross-infection measures involving inpatient and outpati-
ent segregation of children colonized with BCC, with no additional
environmental measures, effectively interrupted the progress of
the outbreak. The introduction of complete cohort segregation of
adult inpatient and outpatients at a UK center led to a reduction in
incidence and prevalence of BCC [68].
4.1.4. Other supporting evidence for the role of cohort
segregation
Agodi et al. [69] introduced new infection control measures,
including cohort segregation, which arrested a BCC epidemic
in several Italian CF centers. Festini et al. [70] noted that the
prevalence of multi-resistant PA was lower in Italian centers
with segregation policies. However, they did not state whether
these were in inpatients, outpatients or both. Greenberg et al.
[71] showed that through cohort segregation there was no
direct spread during the summer camps by the dead-sea.
However, only small numbers took part and follow up was
limited to the three weeks duration of the camp.
4.2. Individual segregation
4.2.1. Inpatient individual segregation
Single patient rooms are recommended in infection control
guidelines from the US, UK and Australia [49–53] (Table 2). We
found no studies looking at individual segregation of inpati-
ents as a stand-alone intervention.
4.2.2. Combined inpatient and outpatient individual
segregation
The standard in the Netherlands is for strict individual isolation
of CF patients as both inpatients and outpatients regardless of
infection status. Van Mansfield et al. [72] looked at PA acquisi-
tion before and after implementation of individual isolation.
They found that PA acquisition declined though this was not
statistically significant. There were no new acquisitions with
the epidemic ST406 strain (which is a strictly CF-related strain)
among non-infected patients after segregation, indicating that
segregation prevented the spread of epidemic clones.
4.3. Hand hygiene
Zuckerman et al. [73] looked at the effectiveness of hand hygiene
in preventing bacterial contamination in CF clinics. They showed
that use of alcohol-based hand hygiene products effectively
reduced hand carriage of respiratory pathogens, but that acqui-
sition of new organisms on hands can occur during clinic visits
suggesting that repeated hand hygiene is needed to control the
risk of recurrent contamination.
4.4. Face masks
In a laboratory cough rig Wood et al. [24] investigated the efficacy
of various face masks and cough etiquette (covering mouth with
the hand while coughing) in reducing cough aerosols of PA gen-
erated by people with CF. They found that both surgical and N95
face masks significantly reduced the amount of PA which can be
recovered from aerosols, with surgical masks being favored by
patients for comfort. Cough etiquette resulted in about half the
reduction of that found with masks. Stockwell et al. [74] looked at
the efficacy of wearing masks over different time periods (10, 20
and 40 min). They concluded that face masks worn for clinically
relevant time periods are effective at reducing the release of
potentially infectious aerosols during coughing in people with
CF. Again surgical masks were found to be more comfortable
than the N95 ones. However, Zuckerman et al. [75] compared
room contamination rates between patients wearing surgical
masks and those without and found similar contamination rates
between the twogroups. The Stockwell andWood studies support
the recommendation, made in US infection control guidelines for
CF [50] which says thatmasks should beworn by CF patients while
they are in a health-care facility. However, it has recently been
suggested that masks need only be worn in communal areas and
not, for example, in the patient’s own side room [76].
4.5. Combination of strategies
Several studies looked at the efficacy of a combination of infec-
tion control strategies. After suspecting nosocomial acquisition
of PA in 12 out of 40 of their patients over a 4-year period,
Tummler et al. [77] looked into the effect cohort segregation of
both inpatients and also physiotherapy outpatient classes had
on PA acquisition. Following the introduction of these measures,
there was only one case of nosocomial acquisition during the
subsequent two years. Chen et al. [56] showed that multiple
infection prevention measures including cohorting of inpatients,
wearing of personal protective equipment when out of bed-
rooms, a hospital-wide education program on infection control
and cohorting of outpatient clinics with mandatory facemasks in
waiting rooms decreased annual incidence of BCC from 8.8% at
baseline to less than 1%. Savant et al. [78] compared respiratory
organism culture rates in patients before and after the introduc-
tion of a new infection control process in children’s outpatient
clinics. Regardless of organism status, all patients underwent
individual isolation during clinic appointments. Alongside this,
strict hygiene measures were instigated and an education pro-
gram for health-care providers, patients and families com-
menced. There were statistically significant drops in both PA
and MRSA rates following these measures. Matt et al. [79] looked
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at the genetic diversity of PA in their center following implemen-
tation of an infection control package comprising: strict indivi-
dual isolation measures; wearing of masks by patients; wearing
of masks, gowns and gloves by clinical staff; thorough disinfec-
tion of clinical areas and equipment; home hygiene advice; and
discouraging CF patients from mixing. Genetic analysis showed
heterogeneity of PA isolates in the majority of patients and no
transmission of PA isolates between CF patients under their care,
indicating the success of the intervention. Wiehlmann et al. [80]
also showed that cohort segregation and hygiene measures
prevented cross-infection of PA between patients in their
Hanover center. After an outbreak of M. abscessus subsp massi-
liense, Kapnadak et al. [81] showed that no newly acquired cases
were identified after strict infection control interventions were
implemented, including source investigation, education, isola-
tion, high priority culture alerts, clinic environment sterilization,
treatment, and surveillance. Kim et al. [82] looked into incidence
or prevalence of pathogenic bacteria in their center’s first year
after implementation of the new CF Foundation Infection
Control Guidelines. They found no significant differences, how-
ever, the follow-up period was short.
4.6. Social events
Smyth et al. [83] noted that on cessation of Adult CF Association
meetings in the local area, no new isolates of BCC occurred.
4.7. Equipment strategies
Jakobsson et al. [29] looked at bacterial contamination rates in
home nebulizers of CF patients. They found that although
contamination rates were generally low, those that were con-
taminated were those that had inadequately followed disin-
fection recommendations or drying. In this study, none of the
patients were colonized with the contaminating organisms
suggesting environmental acquisition rather than the device
being infected from the patient. Fishman et al. [84] looked into
how often nebulizer mask and tubing should be changed. On
comparing two groups consisting of children and young
adults, they found that changing equipment every 12 months
led to similar clinical outcomes as changing every 6 months
with no difference in PA growth after 2 years. Greenwood et al.
[85] studied contamination of a dry-powder inhaler vs.
a nebulizer and suggested that the dry powder device has
a lower contamination rate. One patient in the Greenwood
study had the same organism (S.aureus) isolated from both
sputum and the device, however the other 11 patients with
contaminated devices did not have the same organism iso-
lated from their sputum. This study was sponsored by the
pharmaceutical company which marketed the dry powder
device.
4.8. Adherence to infection prevention strategies
Adherence at Irish CF centers to the 2013 CFF guidelines was
evaluated by Breen et al. [86]. They found 100% adherence to
inpatient guidelines but found that no center adhered to
outpatient mask wearing or room ventilation guidelines.
Overall adherence ranged from 64% to 77%.
4.8.1. Education of staff and inpatients
Re-education of all ward staff and inpatients through videos and
introductionof ‘safe-zone’decals on floorswas shown to improve
patient and staff adherence to infection control policy [87].
5. Conclusion
From the 36 studies included in this systematic review, the
majority have focussed on segregation methods for infection
control. Although deemed low or very low quality, the abun-
dance of studies showing reduction in the spread of transmis-
sible organisms after the introduction of segregation measures
cannot be ignored. All the guidelines included here recom-
mend single patient rooms for inpatients.
Recent studies have shown that facemasks are effective at
reducing the release of potential infective Pseudomonas aero-
sols. These studies were carried out in adults who reported the
wearing of facemasks to be tolerable. The tolerability to chil-
dren and for greater lengths of time are yet to be determined.
As with all areas, policies and strategies are only effective if
the relevant people adhere to them. Regular re-education of
clinical and non-clinical staff as well as people with CF and
their carers improve adherence.
Acquisition of pathogenic organisms can occur through
person-to-person transmission, from the healthcare environ-
ment and environmental reservoirs. We have summarised the
evidence supporting strategies to prevent spread from the
first two sources but have not found any data for strategies
to prevent acquisition from environmental sources.
6. Expert opinion
We have found no high-quality evidence supporting infection
prevention and control measures in CF. Despite this, infection
control guidelines are widely implemented in CF centers globally.
We identified two previously published systematic reviews on the
topic of infection prevention and control in CF. In 2004 Vonberg
et al. [88] identified 102 studies which fitted their inclusion criteria
and graded the quality of evidence using a 5-point scale. They
presented results only for the papers which scored two or more
points on this scale. They separated studies into those inwhich the
authors supported segregation and those in which segregation
was not supported, finding that 31/39 authors supported segrega-
tion. Festini et al. [89] also concentrated on the question of segre-
gation. They identified 10 studies, none of which were RCTs. The
authors concluded that whilst the studies were of generally low
quality, in view of the ethical constraints of prospective, controlled
studies sufficient evidence exists to recommend segregation.
The most recent guideline for infection control practices in CF
is the UK National Institute for Health and Care Excellence (NICE)
guideline published in late 2017 [49]. This identified 16 eligible
studies examining infection prevention and control practices,
including segregation (cohort and individual), use of personal
protective equipment and any combination of these. Ultimately
they recommend a combination of cohort segregation in the clinic
setting and individual rooms with ensuite facilities for in-patients,
whilst grading all the evidence (using the GRADE tool) as low or
very low as shown in Table 2.
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Undertaking RCTs into infection prevention and control stra-
tegies is ethically difficult. Acquisition of transmissible organisms
is associated with worse clinical status. Evidence for segregation
is of limited quality but is abundant and the consistent conclu-
sion is that segregation is beneficial in reducing the spread of
transmissible organisms. In this situation exposing patients to
the risk of cross-infection, in the setting of an RCT, may be
unethical. For those measures, such as negative pressure
rooms, where there may be equipoise amongst clinicians, trials
may be more ethically acceptable. However, such trials would be
expensive and (given current acquisition rates of epidemic
strains) would require long term follow up. Designing trials of
the efficacy of individual elements of an infection control pack-
age would be challenging.
Large-scale epidemiological registry studies may provide
a strategy to answer some of these questions. Most geo-
graphic areas that have a population with CF have their own
registries: the UK CF Trust, the US CF Foundation, and the
European CF Society all collect data on infection. Data
showing year-on-year prevalence of organisms and infection
control measures undertaken at each center may help provide
more evidence to underpin infection control guidelines.
The benefits of infection prevention and control measures
must be balanced against the degree to which they intrude
upon the lives of people with CF. Health professionals may
give parents of children with CF advice regarding measures to
reduce infection in the home which results in a great deal of
parental anxiety and yet there may be little robust evidence
for such advice [90]. In both parents of children and adults
with CF, fear of infection with PA may lead to great anxiety
and inappropriate avoidance measures [91].
Antimicrobial resistancehas always been a feature of theorgan-
isms causing pulmonary infection in people with CF. Initially, this
was exemplified by PA which has intrinsic resistance to many
antibiotics and which can acquire resistance through the expres-
sion of efflux pumps [92] and through the biofilmmode of growth
[93]. More recently, other highly resistant organisms, which origi-
nate in the environment, such as BCC [21] and M. abscessus com-
plex [20] have found aniche in theCF lung andmaybe transmitted
between patients. Effective eradication of these organisms is diffi-
cult or impossible and so primary prevention through infection
prevention and control will be critical over the next 5 years. The
evidence around facemasks is a relatively recent area with more
questions still to be answered. Most CF centers do not have com-
munalwaiting areas; however, facemasksmay be effective in other
areas where patient to patient contact may occur such as phar-
macy or the X-ray department. There is currently no evidence to
support the use of facemasks outside the CF center to prevent
transmission from environmental sources. Wearing of facemasks
may have considerable psychological effects on the person with
CF. With increasing use of digital technology, face to face contact
between the person with CF and the clinical teammay be needed
less frequently. Reducing the need to attend clinics in person,
through the use of digital technology, would lessen the cross-
infection risk. Regimens comprising multiple antibiotics are
a significant burden for the person with CF and carry the risk of
drug-related toxicity. Effective, evidence-based, infection preven-
tion and control strategies may, therefore, allow CF clinicians to
promote antimicrobial stewardship more effectively.
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